- Home
- CAC vs KROS Comparison
CAC vs KROS Comparison
Compare CAC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | KROS |
|---|---|---|
| Founded | 1875 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 565.0M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CAC | KROS |
|---|---|---|
| Price | $43.09 | $21.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $47.33 | $22.20 |
| AVG Volume (30 Days) | 64.9K | ★ 1.2M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | 1.57 |
| Revenue | $215,172,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $44.50 | $6,876.34 |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ $12.35 | $13.67 |
| Revenue Growth | 27.50 | ★ 37798.31 |
| 52 Week Low | $34.53 | $9.12 |
| 52 Week High | $47.55 | $72.37 |
Technical Indicators
Market Signals| Indicator | CAC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 69.15 | 76.91 |
| Support Level | $41.38 | $16.75 |
| Resistance Level | $41.60 | $22.55 |
| Average True Range (ATR) | 1.16 | 1.08 |
| MACD | 0.29 | 0.44 |
| Stochastic Oscillator | 93.26 | 82.21 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.